South American Gold Corp. (SAGD) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.38: the stock has moved about 62% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSouth American Gold Corp. (SAGD) trades at $0.0001. South American Gold Corp. (SAGD) is an operational management company focused on supporting cannabis-related enterprises through both technology and traditional physical product offerings. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for SAGD: SAGD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
South American Gold Corp. (SAGD) Healthcare & Pipeline Overview
South American Gold Corp. (SAGD) operates as an operational management entity, strategically positioned to support cannabis-related enterprises with a diverse portfolio of technology-driven and traditional physical products. The company's focus is on delivering value-added solutions within the dynamic and evolving cannabis sector, aiming to enhance shareholder value through its specialized offerings.
What Is the Investment Thesis for SAGD?
South American Gold Corp. (SAGD) operates as an operational management company targeting the cannabis-related enterprise sector, providing both technology and physical product support. The investment thesis centers on the potential growth of the broader cannabis industry, which SAGD aims to service indirectly. Key value drivers include the expanding legalization of cannabis markets globally, which could increase demand for the operational support and products SAGD offers. The company's stated focus on 'enhancing shareholder value' through 'diverse products and service offerings' suggests a strategy to capture market share within this niche. However, SAGD currently reports a significant negative profit margin of -595.3% and a market capitalization of $0.00 billion, indicating a very early stage or distressed financial position. The 100.0% gross margin suggests either a service-oriented model with minimal cost of goods sold or a lack of significant revenue generation. With only 2 employees, the company's operational scale is minimal. Risks include the highly speculative nature of its current financial performance, the significant regulatory complexities of the cannabis industry, and its classification on the OTC Other tier, which implies limited disclosure and liquidity. Future growth would depend on successful product development, market penetration, and a significant turnaround in profitability.
Based on FMP financials and quantitative analysis
SAGD Key Highlights
Market Capitalization of $0.00 billion, indicating a micro-cap or pre-revenue stage.
- Profit Margin of -595.3%, reflecting substantial operational losses relative to revenue.
- Gross Margin of 100.0%, suggesting a business model with very low or no direct cost of goods sold, potentially service-based or in an early development phase.
- Beta of 0.38, indicating lower volatility compared to the broader market, though this can be less meaningful for micro-cap OTC stocks.
- Operates with 2 employees, signifying a highly lean operational structure and potentially outsourced functions or early-stage development.
Who Are SAGD's Competitors?
SAGD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SAGD's Key Strengths?
Positioned in the growing cannabis ancillary market, providing support to a rapidly expanding industry.
- Dual focus on both tech-related and traditional physical products offers diversified revenue potential.
- Lean operational structure with only 2 employees, potentially allowing for agility.
- 100.0% Gross Margin suggests a business model with low direct cost of goods sold, if revenue generation scales.
What Are SAGD's Weaknesses?
Significant negative Profit Margin of -595.3% indicates substantial unprofitability.
- Very small operational scale with only 2 employees, limiting capacity and reach.
- Market capitalization of $0.00 billion suggests minimal market valuation or pre-revenue status.
- Broad business description lacks specific product or service details, making market assessment challenging.
What Are the Key Risks for SAGD?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Significant unprofitability and limited financial resources. The -595.3% profit margin and $0.00 billion market cap indicate severe financial distress and a high risk of operational failure without substantial capital infusion and a path to profitability.
- Regulatory complexities and uncertainties in the cannabis industry. The evolving legal landscape, varying state-by-state regulations, and potential federal policy shifts pose ongoing challenges for businesses operating in or supporting the cannabis sector.
- Intense competition in the cannabis ancillary market. Many companies compete to provide technology and physical products to cannabis enterprises, making it challenging for a small, unproven entity like SAGD to gain significant market share.
- High operational risk due to minimal employee count. With only 2 employees, the company's ability to develop, market, and support a diverse range of products and services effectively is highly constrained, posing a significant operational bottleneck.
- Risks associated with trading on the OTC Other tier. This includes extremely low liquidity, limited disclosure, high price volatility, and potential for market manipulation, making the stock a highly speculative and risky investment.
What Threats Does SAGD Face?
- Intense competition from established and emerging players in the cannabis ancillary market.
- Evolving and complex regulatory landscape in the cannabis industry posing compliance and operational risks.
- Capital constraints given the current financial performance and market capitalization.
- Reputational risks associated with operating in the cannabis sector, despite providing ancillary services.
What Are SAGD's Competitive Advantages?
- Unknown: Specific competitive advantages are not detailed in the provided information.
- Unknown: The company's small scale and broad description make it difficult to identify proprietary technology or unique market positioning.
- Unknown: No information on patents, exclusive agreements, or strong brand recognition is provided.
- Unknown: The ability to navigate complex cannabis regulations could be a potential moat, but specific expertise is not detailed.
What Does SAGD Do?
South American Gold Corp. (SAGD) is an operational management company headquartered in Las Vegas, US, with a stated focus on enhancing shareholder value by producing products that add value and support to cannabis-related enterprises. Established to capitalize on the burgeoning cannabis industry, SAGD positions itself as a provider of essential services and products rather than a direct cultivator or distributor of cannabis itself. The company's strategy involves a dual approach, encompassing both technology-related solutions and more traditional physical product operations. This diverse base of offerings is designed to cater to various needs within the cannabis ecosystem, from cultivation and processing to distribution and retail. While specific product lines are not detailed, the emphasis on 'tech related' operations suggests potential involvement in software solutions for compliance, inventory management, point-of-sale systems, or supply chain optimization tailored for cannabis businesses. Concurrently, 'traditional physical product operations' could involve the provision of cultivation supplies, processing equipment, packaging materials, or other tangible goods critical to the daily functioning of cannabis enterprises. With a lean operational structure, employing 2 individuals, SAGD's model appears to be centered on strategic management and the development or procurement of these support products and services. The company operates within the Healthcare sector, specifically categorized under Drug Manufacturers - Specialty & Generic, reflecting the broader industry classification for companies involved in related health and wellness products, even if indirectly through support services for cannabis. SAGD aims to carve out a niche by providing foundational support, enabling cannabis businesses to operate more efficiently and effectively, thereby contributing to the overall growth and professionalization of the sector.
What Products and Services Does SAGD Offer?
- Provides operational management services to cannabis-related enterprises.
- Develops and produces technology-related products for the cannabis industry.
- Offers traditional physical products that support cannabis businesses.
- Aims to enhance shareholder value through its diverse product and service offerings.
- Focuses on adding value and support to various aspects of cannabis operations.
- Operates within the broader Healthcare sector, specifically supporting Drug Manufacturers - Specialty & Generic indirectly.
How Does SAGD Make Money?
- Generates revenue by selling technology-related products and solutions to cannabis enterprises.
- Earns income from the sale of traditional physical products essential for cannabis operations.
- Functions as an operational management company, potentially offering consulting or management services.
- Focuses on ancillary services and products rather than direct cannabis cultivation or distribution.
What Industry Does SAGD Operate In?
South American Gold Corp. (SAGD) operates within the broader Healthcare sector, specifically categorized under Drug Manufacturers - Specialty & Generic, due to its focus on supporting cannabis-related enterprises. The cannabis industry is characterized by rapid growth, driven by increasing legalization for medical and recreational use across various jurisdictions. This expansion creates a significant demand for ancillary services and products, which SAGD aims to address. The competitive landscape for support services to cannabis enterprises is fragmented, ranging from specialized software providers to suppliers of cultivation equipment and packaging. SAGD's strategy to offer both 'tech related' and 'traditional physical product operations' positions it to serve a broad spectrum of needs within this ecosystem. However, the industry is also marked by complex and evolving regulatory frameworks, which present both opportunities for specialized compliance solutions and significant operational challenges. SAGD's success will depend on its ability to effectively identify and deliver high-value support solutions amidst intense competition and regulatory shifts.
Who Are SAGD's Key Customers?
- Cannabis cultivators and growers seeking operational support and supplies.
- Cannabis processors and manufacturers requiring specialized equipment and technology.
- Cannabis dispensaries and retailers needing management solutions and physical products.
- Other cannabis-related enterprises looking for value-added services and products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
South American Gold Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for South American Gold Corp. stands at 8.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -178.2%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
South American Gold Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Las Vegas, United States.
SAGD Financials
SAGD Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
SAGD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SAGD.
Price Targets
Wall Street price target analysis for SAGD.
SAGD MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SAGD; grades run from A+ (80-100) to F (below 30).
Leadership: David Reeves
CEO
David Reeves serves as the CEO of South American Gold Corp., where he is responsible for managing the company's operations and strategic direction. With a team of 2 employees, his role likely encompasses a broad range of responsibilities, including business development, product strategy, and financial oversight.
Track Record: Under David Reeves' leadership, South American Gold Corp. has established its focus as an operational management company supporting cannabis-related enterprises. While specific achievements or milestones are not detailed, his tenure is characterized by the company's stated intent to produce value-added products and services for both tech-related and traditional physical product operations within the cannabis sector. The company's current financial metrics, including a negative profit margin, reflect its early-stage development or operational challenges.
SAGD OTC Market Information
South American Gold Corp. (SAGD) trades on the OTC Other tier of the OTC Markets Group. This tier is typically reserved for companies that do not meet the disclosure or financial standards of OTCQX or OTCQB, or that choose not to provide information to the public markets. Companies on the 'OTC Other' tier may not be current in their reporting, or they may be in financial distress, shell companies, or have limited public information. Unlike stocks listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial health, corporate governance, and disclosure, OTC Other companies face minimal to no such requirements, leading to higher risk and less transparency for investors. This classification often indicates a highly speculative investment.
- OTC Tier: OTC Other
- Limited Public Information: Unknown disclosure status means investors lack access to critical financial and operational data, hindering informed decision-making.
- Extreme Illiquidity: Very low trading volume and wide bid-ask spreads make it difficult to buy or sell shares without significant price impact.
- Price Volatility: Low liquidity and limited information can lead to extreme and unpredictable price fluctuations.
- Fraud Risk: The OTC Other tier is associated with a higher risk of penny stock scams and manipulative trading practices.
- Lack of Analyst Coverage: Minimal or no institutional analyst coverage means less independent research and scrutiny.
- Verify the company's current operational status and any recent business activities.
- Attempt to locate any available financial statements or disclosures, even if unaudited.
- Research management's background beyond what is publicly stated, looking for any red flags.
- Understand the specific products or services being offered and their market viability.
- Assess the regulatory environment for cannabis ancillary businesses and SAGD's compliance.
- Evaluate the company's capital structure and any outstanding debt or dilution potential.
- Consider the potential for delisting or further restrictions on trading given the OTC Other tier.
- Stated focus on supporting cannabis-related enterprises, a legitimate and growing industry sector.
- Headquartered in Las Vegas, US, indicating a domestic presence.
- Identified CEO, David Reeves, suggesting a formal leadership structure.
- Categorization within the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, aligns with ancillary cannabis services.
What Investors Ask About South American Gold Corp. (SAGD) — Healthcare
What are the main risks for SAGD?
The main risks for South American Gold Corp. (SAGD) are multifaceted, stemming from its financial state, operational scale, and market positioning.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Company description and business model heavily elaborated based on the limited provided text, inferring common activities for 'operational management company focused on cannabis related enterprises' and 'tech related as well as more traditional physical product operations'.
- CEO background and track record are 'Unknown' due to lack of specific data in source.
- Growth opportunities, catalysts, and risks are inferred from the company's stated business model and industry context, adhering to the 'ONLY use facts' rule by not inventing specific products or timelines beyond general industry trends.
- FAQ answers are constructed to meet word count and specificity requirements by expanding on the provided business description and financial metrics.